Study: Biontech vaccine produces “much higher” antibodies than Sinovac

A study conducted in Hong Kong and published by the South China Morning Post today revealed that the antibody levels of those who received the Biontech vaccine to prevent Covid-19 were "significantly higher" than those who received the Sinovac vaccine.

 The newspaper, quoting Benjamin Cowling, professor of epidemiology at the University of Hong Kong and lead researcher on the study, said that some of those who received the Sinovac vaccine may also need a third booster dose.

 The report indicated that the study, conducted by the College of Public Health of the University of Hong Kong, commissioned by the government, monitored the production of antibodies in 1,000 people who received one of the two vaccines.

 Last week, officials in Indonesia warned that more than 350 medical workers had contracted COVID-19 despite being vaccinated with Sinovac and that dozens had been hospitalized, raising concerns about the vaccine's efficacy with the most contagious mutant of the coronavirus.

 Uruguay this month published factual data on the impact of the Sinovac Biotech vaccine among its population, and the data showed that the vaccine was more than 90 percent effective in preventing admission to intensive care units and death.

 The Uruguayan government also studied the effectiveness of the Pfizer/Biontech vaccine among 162,047 health workers or over 80 years old, and said it recorded a 94 percent effectiveness in preventing admission to intensive care units and death and reducing infections by 78 percent.

Follow our latest local and sports news and the latest political and economic developments via Google news